Trials / Recruiting
RecruitingNCT06676982
Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A phase I clinical study of the safety and tolerability, efficacy of CNCT19 CAR T-cell therapy in patients with advanced hepatocellular carcinoma hepatocellular carcinoma.
Detailed description
This is a single-arm, dose-escalation, open, exploratory clinical study to evaluate the safety and tolerability, preliminary efficacy and PK/PD haracteristics of CNCT19 CAR T-cell therapy in the treatment of advanced hepatocellular carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | anti-CD19 CAR-T | All subjects were intravenous administrated with CNCT19 CAR-T. |
Timeline
- Start date
- 2025-01-10
- Primary completion
- 2026-07-30
- Completion
- 2026-08-31
- First posted
- 2024-11-06
- Last updated
- 2025-12-15
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06676982. Inclusion in this directory is not an endorsement.